It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The blood–brain barrier (BBB) is limiting transcellular and paracellular movement of molecules and cells, controls molecular traffic, and keeps out toxins. However, this protective function is the major hurdle for treating brain diseases such as brain tumors, Parkinson’s disease, Alzheimer’s disease, etc. It was previously demonstrated that high pulsed electrical fields (PEFs) can disrupt the BBB by inducing electroporation (EP) which increases the permeability of the transcellular route. Our goal was to study the effects of low PEFs, well below the threshold of EP on the integrity and function of the BBB. Ten low voltage pulses (5–100 V) were applied to a human in vitro BBB model. Changes in permeability to small molecules (NaF) were studied as well as changes in impedance spectrum and trans-endothelial electric resistivity. Viability and EP were evaluated by Presto-Blue and endogenous Lactate dehydrogenase release assays. The effect on tight junction and adherent junction protein was also studied. The results of low voltage experiments were compared to high voltage experiments (200–1400 V). A significant increase in permeability was found at voltages as low as 10 V despite EP only occurring from 100 V. The changes in permeability as a function of applied voltage were fitted to an inverse-exponential function, suggesting a plateau effect. Staining of VE-cadherin showed specific changes in protein expression. The results indicate that low PEFs can transiently disrupt the BBB by affecting the paracellular route, although the mechanism remains unclear.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Advanced Technology Center, Sheba Medical Center, Ramat Gan, Israel;
2 The Advanced Technology Center, Sheba Medical Center, Ramat Gan, Israel;; The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel;; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel;
3 The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel;
4 The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel;; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
5 Blood-Brain Barrier Laboratory (LBHE), Université d’Artois, Lens, France;
6 The Advanced Technology Center, Sheba Medical Center, Ramat Gan, Israel;; Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel;
7 The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel;; Interdisciplinary Center Herzliya, Herzliya, Israel